JPMorgan Europe Research Enhanced Index Equity Active (ETR:JREE)
Germany · Delayed Price · Currency is EUR 50.92
-0.06 (-0.12%)
Apr 2, 2026, 5:36 PM CET
13.07% (1Y)
| Assets | 2.54B |
| Expense Ratio | 0.25% |
| PE Ratio | 10.22 |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +13.07% |
| Volume | 9,422 |
| Open | 50.43 |
| Previous Close | 50.98 |
| Day's Range | 50.18 - 51.01 |
| 52-Week Low | 38.91 |
| 52-Week High | 54.27 |
| Beta | 0.99 |
| Holdings | 156 |
| Inception Date | Oct 10, 2018 |
About JREE
The Sub-Fund aims to achieve a long-term return in excess of MSCI Europe Index (Total Return Net) (the "Benchmark") by actively investing primarily in a portfolio of European companies.
Asset Class Equity
Category Total Market
Stock Exchange Deutsche Börse Xetra
Ticker Symbol JREE
Provider JPMorgan
Performance
JREE had a total return of 13.07% in the past year, including dividends. Since the fund's inception, the average annual return has been 10.53%.
Top 10 Holdings
23.57% of assets| Name | Symbol | Weight |
|---|---|---|
| ASML Holding N.V. | ASML | 4.41% |
| AstraZeneca PLC | AZN | 2.75% |
| HSBC Holdings plc | HSBA | 2.20% |
| Nestlé S.A. | NESN | 2.19% |
| Shell plc | SHEL | 2.16% |
| Roche Holding AG | ROC1.L | 2.14% |
| Novartis AG | NOVN | 2.07% |
| Siemens Aktiengesellschaft | SIE | 1.99% |
| Allianz SE | ALV | 1.91% |
| Banco Santander, S.A. | SAN | 1.75% |